

AMENDMENT OF THE CLAIMS

Please amend the claims as follows. This listing of claims will replace all prior versions and listings of claims in the application.

Claims 1-25. (Cancelled)

26. (Previously presented) A method for treating atherosclerosis in a human or animal comprising administering to the human or animal a composition comprising an effective angiogenesis-inhibiting amount of 2-methoxyestradiol.

27. (Currently amended) A method for treating tumors in a human ~~or animal~~ comprising administering to the human ~~or animal~~ a composition comprising an effective angiogenesis-inhibiting amount of 2-methoxyestradiol, wherein the tumors are ~~selected from~~ solid tumors, benign tumors, or metastatic tumors.

28. (Previously presented) The method of Claim 27, wherein the tumors are solid tumors.

29. (Previously presented) The method of Claim 27, wherein the tumors are benign tumors.

30. (Previously presented) The method of Claim 27, wherein the tumors are metastatic tumors.

31. (Previously presented) The method of Claim 29, wherein the benign tumors are selected from hemangiomas, acoustic neuromas, neurofibromas, trachomas, or pyogenic granulomas.

32. (Previously presented) A method for treating nerve cell diseases in a human or animal comprising administering to the human or animal with the nerve cell disease a composition comprising an effective angiogenesis-inhibiting amount of 2-methoxyestradiol, wherein the nerve cell disease is selected from acoustic neuroma or neurofibroma.

33. (Cancelled).

34. (Previously presented) A method for treating diseases of the eye in a human or animal comprising administering to the human or animal with a disease of the eye a composition comprising an effective angiogenesis-inhibiting amount of 2-methoxyestradiol, wherein the disease of the eye is selected from trachomas, retinopathy of prematurity, diabetic retinopathy, retrolental fibroplastic, macular degeneration, corneal graft rejection or neovascular glaucoma.

35. (Cancelled).

36. (Previously presented) A method for treating inflammation in a human or animal comprising administering to the human or animal with inflammation a composition comprising an angiogenesis-inhibiting amount of 2-methoxyestradiol.

37. (Previously presented) The method of Claim 36, wherein the inflammation is associated with pyogenic granulomas, vascular malfunctions, abnormal wound healing, inflammatory disorders, gout, gouty arthritis, rheumatoid arthritis, psoriasis or immune disorders.

38. (Previously presented) A method for treating Behcet's syndrome in a human comprising administering to the human with Behcet's syndrome a composition comprising an effective angiogenesis-inhibiting amount of 2-methoxyestradiol.

39. (Previously presented) A method for treating Osler-Weber syndrome in a human comprising administering to the human with Osler-Weber syndrome a composition comprising an effective angiogenesis-inhibiting amount of 2-methoxyestradiol.

40. (Previously presented) A method of treating undesired angiogenesis associated with ovulation, implantation of a blastula, or menstruation in a human or animal comprising administering to the human or animal a composition comprising an effective angiogenesis-inhibiting amount to 2-methoxyestradiol.

41. (Cancelled).

42. (Cancelled).

Please add new Claim 43 as follows:

43. (New) A method of inhibiting excessive or abnormal stimulation of endothelial cells in a human or an animal comprising administering to the human or animal a composition comprising an effective angiogenesis-inhibiting amount to 2-methoxyestradiol.